tbuckley/cabot-search huggingface dataset:
Perceptions of stress in adolescent and young adult (AYA) cancer patients and survivors in Kansas City, KS, and Copenhagen, Denmark: A pilot study.
Authors: Abbey Elsbernd, Christopher Crenner, Kirsten Boisen, Hanne Bækgaard Larsen, Maiken Hjerming, Thomas W. Loew, Tarris Rosell, Jyoti Panicker
Journal: Journal of Clinical Oncology (2017)

186 Background: Adolescent and Young Adult (AYA) Oncology is a developing field of medicine with unique challenges in the clinical setting. People at this stage of life face many difficulties, which may be compounded by lack of insurance coverage and barriers in accessing health care resources. The goal of this pilot study is to examine how stress levels and psychosocial well-being are affected by healthcare system, insurance status, and other AYA-specific factors. Methods: 38 AYA patients ages 15-30 who have received, or are currently receiving treatment for an oncology diagnosis completed an online survey and 10-item interview, with 29 patients at University of Kansas Medical Center, Kansas City, United States, and 9 patients at Rigshospitalet, Copenhagen, Denmark. Survey measures included the Perceived Stress Scale (PSS) standardized tool, and questions relating to patient concerns, resources utilized, and general thoughts on healthcare. Results: Differences in quantitative stress levels were not significant between the two study sites. In Kansas City, female gender was identified as a significant variable for increased PSS values. In addition, Kansas City patients expressed increased reported practical concerns, such as the role of social workers, transportation, insurance, and disruptions in work and school life due to treatment. Danish patients expressed more positive practical concern statements, citing Danish government resources such as physical therapy and psychiatry services. Qualitative data for both sites placed highest emphasis on the connection that AYA patients have with their healthcare team. Both U.S. and Danish patients reported diverse concerns and positive experiences. Conclusions: AYA oncology patients are a diverse group who have not yet been sufficiently studied, and face many struggles that are unique to this age group. More research on a broad scale is needed, as the data collected in this study suggest results that may prove significant with more time available and larger patient sample sizes. The first author of this abstract has been selected as a semifinalist by the Fulbright commission to expand this pilot project in 2017-2018.
FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor
Authors: Leili Ran, Yuedan Chen, Jessica Sher, Elissa W.P. Wong, Devan Murphy, Jenny Q. Zhang, Dan Li, Kemal Deniz, Inna Sirota, Zhen Cao, Shangqian Wang, Youxin Guan, Shipra Shukla, Katie Yang Li, Alan Chramiec, Yuanyuan Xie, Deyou Zheng, Richard P. Koche, Cristina R. Antonescu, Yu Chen, Ping Chi
Journal: Cancer Discovery (2017)

The cellular context that integrates upstream signaling and downstream nuclear response dictates the oncogenic behavior and shapes treatment responses in distinct cancer types. Here, we uncover that in gastrointestinal stromal tumor (GIST), the forkhead family member FOXF1 directly controls the transcription of two master regulators, KIT and ETV1, both required for GIST precursor-interstitial cells of Cajal lineage specification and GIST tumorigenesis. Further, FOXF1 colocalizes with ETV1 at enhancers and functions as a pioneer factor that regulates the ETV1-dependent GIST lineage-specific transcriptome through modulation of the local chromatin context, including chromatin accessibility, enhancer maintenance, and ETV1 binding. Functionally, FOXF1 is required for human GIST cell growth in vitro and murine GIST tumor growth and maintenance in vivo The simultaneous control of the upstream signaling and nuclear response sets up a unique regulatory paradigm and highlights the critical role of FOXF1 in enforcing the GIST cellular context for highly lineage-restricted clinical behavior and treatment response.Significance: We uncover that FOXF1 defines the core-regulatory circuitry in GIST through both direct transcriptional regulation and pioneer factor function. The unique and simultaneous control of signaling and transcriptional circuitry by FOXF1 sets up an enforced transcriptional addiction to FOXF1 in GIST, which can be exploited diagnostically and therapeutically. Cancer Discov; 8(2); 234-51. ©2017 AACR.See related commentary by Lee and Duensing, p. 146This article is highlighted in the In This Issue feature, p. 127.
Erratum: Corrigendum: Cxorf6 is a causative gene for hypospadias
Authors: Maki Fukami, Yuka Wada, Kanako Miyabayashi, Ichizo Nishino, Tomonobu Hasegawa, Giovanna Camerino, Christine Kretz, Anna Buj-Bello, Jocelyn Laporte, Gen Yamada, Ken-ichirou Morohashi, Tsutomu Ogata
Journal: Nature Genetics (2006)
A Controlled Trial of Erenumab for Episodic Migraine
Authors: Peter J. Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo H. Bonner, Feng Zhang, Sandhya Sapra, Hernan Picard, Daniel D. Mikol, Robert A. Lenz
Journal: New England Journal of Medicine (2017)

We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.We randomly assigned patients to receive a subcutaneous injection of either erenumab, at a dose of 70 mg or 140 mg, or placebo monthly for 6 months. The primary end point was the change from baseline to months 4 through 6 in the mean number of migraine days per month. Secondary end points were a 50% or greater reduction in mean migraine days per month, change in the number of days of use of acute migraine-specific medication, and change in scores on the physical-impairment and everyday-activities domains of the Migraine Physical Function Impact Diary (scale transformed to 0 to 100, with higher scores representing greater migraine burden on functioning).A total of 955 patients underwent randomization: 317 were assigned to the 70-mg erenumab group, 319 to the 140-mg erenumab group, and 319 to the placebo group. The mean number of migraine days per month at baseline was 8.3 in the overall population; by months 4 through 6, the number of days was reduced by 3.2 in the 70-mg erenumab group and by 3.7 in the 140-mg erenumab group, as compared with 1.8 days in the placebo group (P<0.001 for each dose vs. placebo). A 50% or greater reduction in the mean number of migraine days per month was achieved for 43.3% of patients in the 70-mg erenumab group and 50.0% of patients in the 140-mg erenumab group, as compared with 26.6% in the placebo group (P<0.001 for each dose vs. placebo), and the number of days of use of acute migraine-specific medication was reduced by 1.1 days in the 70-mg erenumab group and by 1.6 days in the 140-mg erenumab group, as compared with 0.2 days in the placebo group (P<0.001 for each dose vs. placebo). Physical-impairment scores improved by 4.2 and 4.8 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 2.4 points in the placebo group (P<0.001 for each dose vs. placebo), and everyday-activities scores improved by 5.5 and 5.9 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 3.3 points in the placebo group (P<0.001 for each dose vs. placebo). The rates of adverse events were similar between erenumab and placebo.Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced migraine frequency, the effects of migraines on daily activities, and the use of acute migraine-specific medication over a period of 6 months. The long-term safety and durability of the effect of erenumab require further study. (Funded by Amgen and Novartis; STRIVE ClinicalTrials.gov number, NCT02456740 .).
Estrategia de la Región europea de la OMS para la eliminación del sarampion
Authors: F X Hanon, J. Spika John, S. Wassilak Steven, N Emiroglu
Journal: Eurosurveillance (2003)

La estrategia de la OMS para la eliminacion del sarampion en Europa incluye el refuerzo de los programas de vigilancia e inmunizacion en colaboracion con determinadas redes europeas (EUVAC.NET y CCEE-Baltic) y con los Estados miembros.
A putative causal relationship between genetically determined female body shape and posttraumatic stress disorder
Authors: Renato Polimanti, Ananda B. Amstadter, Murray B. Stein, Lynn M. Almli, Dewleen G. Baker, Laura J. Bierut, Bekh Bradley, Lindsay A. Farrer, Eric O. Johnson, Anthony King, Henry R. Kranzler, Adam X. Maihofer, John P. Rice, Andrea L. Roberts, Nancy L. Saccone, Hongyu Zhao, Israel Liberzon, Kerry J. Ressler, Caroline M. Nievergelt, Karestan C. Koenen, Joel Gelernter
Journal: Genome Medicine (2017)

The nature and underlying mechanisms of the observed increased vulnerability to posttraumatic stress disorder (PTSD) in women are unclear.We investigated the genetic overlap of PTSD with anthropometric traits and reproductive behaviors and functions in women. The analysis was conducted using female-specific summary statistics from large genome-wide association studies (GWAS) and a cohort of 3577 European American women (966 PTSD cases and 2611 trauma-exposed controls). We applied a high-resolution polygenic score approach and Mendelian randomization analysis to investigate genetic correlations and causal relationships.We observed an inverse association of PTSD with genetically determined anthropometric traits related to body shape, independent of body mass index (BMI). The top association was related to BMI-adjusted waist circumference (WCadj; R = -0.079, P < 0.001, Q = 0.011). We estimated a relative decrease of 64.6% (95% confidence interval = 27.5-82.7) in the risk of PTSD per 1-SD increase in WCadj. MR-Egger regression intercept analysis showed no evidence of pleiotropic effects in this association (Ppleiotropy = 0.979). We also observed associations of genetically determined WCadj with age at first sexual intercourse and number of sexual partners (P = 0.013 and P < 0.001, respectively).There is a putative causal relationship between genetically determined female body shape and PTSD, which could be mediated by evolutionary mechanisms involved in human sexual behaviors.
L’émergence de la LGV en Europe occidentale: état des lieux des connaissances et réponses possibles
Authors: M Jw Van de Laar
Journal: Eurosurveillance (2006)

La lymphogranulomatose venerienne (LGV), est une infection sexuellement transmissible (IST) systemique due a la bacterie Chlamydia trachomatis, qui survient rarement dans le monde occidental [1]. Cependant, en janvier 2004, les responsables de la sante publique aux Pays-Bas ont identifie une epidemie de cas de proctites liees a la LGV chez les hommes ayant des relations sexuelles avec d’autres hommes (HSH) [2]. Depuis lors, des cas ont ete declares dans plusieurs pays d’Europe, ainsi qu’aux Etats-Unis et au Canada. Dans ce numero d’Eurosurveillance, trois pays decrivent leur situation actuelle vis-a-vis de la LGV [3-5].
Assessing the Necessity of Stopping Antithrombotic Agents Before Wide-Awake Hand Surgery
Authors: Sarah E. Sasor, Tyler A. Evans, Julia A. Cook, Elizabeth A. Lucich, William A. Wooden, Sunil S. Tholpady, Michael W. Chu
Journal: JAMA Surgery (2017)

Assessing the Necessity of Stopping Antithrombotic Agents Before Wide-Awake Hand SurgeryMany patients requiring carpal tunnel release (CTR) surgery are taking long-term antithrombotic (AT) agents for various medical conditions.This presents a challenge for hand surgeons, who must weigh the risk of bleeding if AT therapy is continued against the risk of thrombosis if AT therapy is temporarily stopped.3][4] The goal of this study is to evaluate the safety of continuing AT use in the perioperative period in wideawake CTR using an open surgical technique.
Dichotomous Expression of TNF Superfamily Ligands on Antigen-Presenting Cells Controls Post-priming Anti-viral CD4+ T Cell Immunity
Authors: Yu-Han Chang, Kuan Chung Wang, Kuan-Lun Chu, Derek L. Clouthier, Anh T. Tran, Miguel S. Torres Perez, Angela C. Zhou, Ali A. Abdul-Sater, Tania H. Watts
Journal: Immunity (2017)
Abstract 13852: Improved Long-Term Survival With Repeat Coronary Bypass Surgery Compared to Percutaneous Coronary Intervention After Previous Surgical Revascularization a 20 Year Experience
Authors: Lawrence E Greiten, Hartzell V Schaff, John M Stulak, Sameh M Said, Kevin L Greason, Richard C Daly, David L Joyce, Simon Maltais, Brian D Lahr, Courtney N Heins, Joseph A Dearani, Amir Lerman, Chaim Locker
Journal: Circulation (2016)

Introduction: We compared outcome of repeat CABG (RCABG) and PCI in patients with previous CABG. Hypothesis: RCABG may improve survival versus PCI. Methods: From 1993 through 2009, 3,058 patients underwent revascularization after previous CABG. RCABG patients (n=530) were grouped by the use of arterial grafts (n=396), or saphenous vein grafts (SVG; n=134). At previous CABG, 37% of RCABG patients received IMA graft. PCI patients (n=2,528) were grouped into balloon angioplasty (BA; n=491), bare metal stent (BMS; n=1,267), and drug-eluting stent (DES; n=769). PCI patients were further stratified by the treated target into native coronary artery (n=1,637), bypass grafts (n=674), or both (n=216). Propensity score analysis matched 287 patients. Results: RCABG had increased 30-day mortality compared with PCI (HR=3.92; 95% CI, 2.25-6.84; P &lt;.001) in multivariable analysis, while in propensity matched analysis it did not ( P =.09). Overall survival, however, was greater for RCABG compared with PCI in multivariable analysis (HR=0.70; 95% CI, 0.59-0.83; P &lt;.001), as well as in propensity matched analysis (10-year survival rates were 52% vs 37%, respectively [ P =.005]). Compared with RCABG, PCI involving bypass grafts had increased mortality (HR, 1.39; 95% CI, 1.09-1.78; P =.008), whereas PCI targeting only the native coronaries did not (HR, 1.12; 95% CI, 0.85-1.47; P =.43); BMS patients had increased mortality (HR, 1.34; 95% CI, 1.06-1.68; P =.013), but DES did not (HR, 1.28; 95% CI, 0.77-2.12; P =.35). At RCABG, 318 patients (60%) received an IMA graft and late survival was similar to those receiving SVG; The use of IMA in previous CABG was associated with improved survival (HR=0.82; 95% CI, 0.72-0.92; P &lt;.001]. Conclusions: Long-term survival after previous CABG is improved with RCABG compared to PCI, especially when PCI involves bypass grafts. There is no difference in long-term survival between RCABG using arterial grafts vs SVG only if IMA is used in either previous or RCABG.
Abstract 19655: Elevated Oxidative Stress Induces Smooth Muscle Cell Death via Superoxide Anion in Bicuspid Aortic Valve-associated Aortopathy
Authors: Julie A Phillippi, Marie Billaud, Jennifer C Hill, Julianna E Buchwald, Mary P Kotlarczyk, Nadiezhda Cantu-Medéllin, Murugesan Velayutham, Arturo J Cardounel, Eric E Kelley, Thomas G Gleason
Journal: Circulation (2015)

Introduction: Bicuspid aortic valve (BAV) is associated with an aortopathy that manifests as a dilatation of the proximal ascending aorta. The mechanisms of aneurysm formation in BAV patients are not completely understood. Our group established that medial smooth muscle cells (SMC) from aneurysmal BAV patients exhibit a weakened oxidative stress defense. Hypothesis: The weakened oxidative stress defense of medial SMCs in BAV patients leads to elevated oxidative stress in the proximal ascending aorta and decreases SMC viability. Methods: Aortic specimens were harvested from patients undergoing aortic valve and/or ascending aortic replacement due to aneurysm, or heart transplant, with IRB approval and informed patient consent. Levels of the superoxide anion-specific oxidation product 2-OH-E + was detected via HPLC in hydroethidine-exposed fresh human aortic specimens. Lipid peroxidation was quantified by ELISA-based detection of 8-iso-prostaglandin F2α. Superoxide anion (O 2 •- ) production and cell viability in primary SMC were detected using the cytochrome c reduction assay, and the MTT assay respectively. Results: Levels of O 2 •- and lipid peroxidation were elevated in BAV specimens when compared with tricuspid aortic valve (TAV) specimens (8.7 ± 0.90 vs 6.1 ± 0.90 pmol/mg, and 610±32 vs 458±45 pg/mg, Fig A and B respectively). Elevated O 2 •- production was detected in primary SMC in vitro when compared with SMC from TAV patients (13.2 ± 2.9 vs 6.7 ± 1.7 pmol/min/mg, Fig C). Addition of peroxide to primary SMC resulted in intracellular O 2 •- -mediated cell death (Fig D). Conclusions: Our results indicate that accumulation of O 2 •- in SMC is associated with increased oxidative stress and with increased cell death in the setting of BAV. Ongoing studies are focused on defining mechanisms of O 2 •- generation and the impact on aortic wall biomechanics. Importantly, this could help to develop novel interventions for BAV patients who are at risk for aortic catastrophe.
In localized prostate cancer, radical prostatectomy and observation did not differ for mortality at 13 years
Authors: Kari A.O. Tikkinen, Gordon H. Guyatt
Journal: Annals of Internal Medicine (2017)

ACP Journal Club21 November 2017In localized prostate cancer, radical prostatectomy and observation did not differ for mortality at 13 yearsKari A.O. Tikkinen, MD, PhD, Gordon H. Guyatt, MDKari A.O. Tikkinen, MD, PhDUniversity of Helsinki and Helsinki University Hospital, Helsinki, Finland (K.A.T.)Search for more papers by this author, Gordon H. Guyatt, MDMcMaster University, Hamilton, Ontario, Canada (G.H.G.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-167-10-053 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationWilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377:132-42. https://pubmed.ncbi.nlm.nih.gov/28700844References1 Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl. 1995;172:65-72. [PMID: 8578259] Google Scholar2 Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370:932-42. [PMID: 24597866] Google Scholar3 Hamdy FC, Donovan JL, Lane JA, et al; ProtecT Study Group. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415-24. [PMID: 27626136] Google Scholar4 Wilt TJ, Brawer MK, Jones KM, et al; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-13. [PMID: 22808955] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Helsinki and Helsinki University Hospital, Helsinki, Finland (K.A.T.)McMaster University, Hamilton, Ontario, Canada (G.H.G.)This article was published at Annals.org on 7 November 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byUrinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational studyRadical prostatectomy versus deferred treatment for localised prostate cancer 21 November 2017Volume 167, Issue 10Page: JC53KeywordsCancer treatmentHealth care qualityMortalityProstate cancerProstatectomyRadical prostatectomyRelative riskSurgeryVeteran care ePublished: 21 November 2017 Issue Published: 21 November 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Anxiety in breast cancer patients treated with neoadjuvant therapy: Effects on surgical plan and role of supportive care.
Authors: Huaqi Li, Winson Y. Cheung, Paula Myers, Elaine McKevitt, Kaylie Willemsma, Adam Deruchie Tan, Stephen K. L. Chia, Christine E. Simmons
Journal: Journal of Clinical Oncology (2017)

35 Background: The impact of high anxiety on surgical decision making has been demonstrated in various cancer settings. For patients undergoing neoadjuvant therapy (NAT) for breast cancer, supportive services can be offered prior to surgery and may help them choose between the options of bilateral mastectomy, unilateral mastectomy, or breast conserving surgery (BCS) where clinically appropriate. However, the effect of anxiety at initial diagnosis and psychological support on these decisions has not yet been studied. Methods: A prospective database of breast cancer patients treated with NAT at the British Columbia Cancer Agency was utilized to extract demographic information, surgical plan with regards to BCS and unilateral or bilateral mastectomy, and information about supportive services utilized. This was correlated with anxiety scores at initial consultation recorded by the Edmonton Symptom Assessment System and the Psychosocial Screen for Cancer. Patients were excluded if they had bilateral breast cancer, BRCA mutation, or missing data. Fisher’s exact tests were applied for statistical analysis. Results: From 2012-2016, 361 potential patients were identified. In total, 203 patients met eligibility criteria: 93 patients (46%) had low anxiety and 110 patients (54%) had high anxiety. Patients with high self-reported anxiety at initial consultation were 19% more likely to undergo aggressive surgery (bilateral mastectomy for unilateral disease or mastectomy for BCS eligible disease) than those with low self-reported anxiety at initial consultation (37% VS 18%; p = 0.003). Of the 110 patients with high anxiety, only 46 patients (42%) utilized counselling before surgery. No significant difference in rate of aggressive surgery was observed in patients with high anxiety who had counselling compared to those who did not (33% VS 41%; p = 0.43). Conclusions: High anxiety at initial consultation is associated with a 19% increase in aggressive surgery compared to patients with low anxiety. Counselling resources are currently underutilized by eligible patients, but this did not have an impact on surgical decision making in this study. This may be an area of opportunity for further research.
HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage
Authors: Elise Landais, Ben Murrell, Bryan Briney, Sasha Murrell, Kimmo Rantalainen, Zachary T. Berndsen, Alejandra Ramos, Lalinda Wickramasinghe, Melissa Laird Smith, Kemal Eren, Natalia de Val, Mengyu Wu, Audrey Cappelletti, Jeffrey Umotoy, Yolanda Lie, Terri Wrin, Paul Algate, Po-Ying Chan-Hui, Etienne Karita, Andrew B. Ward, Ian A. Wilson, Dennis R. Burton, Davey Smith, Sergei L. Kosakovsky Pond, Pascal Poignard
Journal: Immunity (2017)